( June 10, 2026, 02:25 GMT | Official Statement) -- MLex Summary: Eli Lilly's proposal to wholly acquire Kelonia Therapeutics has been approved by Australia's competition watchdog. In a determination issued on Wednesday, the Australian Competition & Consumer Commission said that there is no horizontal overlap between the assets of Eli Lilly, headquartered in Indianapolis, and US-based biotech company Kelonia Therapeutics in Australia. While Eli Lilly develops and markets pharmaceutical products, including in oncology, Kelonia develops gene therapies, including in vivo CAR‑T treatments for cancer, with its lead program targeting multiple myeloma.Determination is attached....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.